Duquesne Family Office’s Faeth Therapeutics FTH Stock Holding History

Duquesne Family Office’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,000	Closed	-$69K	–	90
2023 Q4	$69K	Hold	5,000	–	–	﹤0.01%	51
2023 Q3	$80K	Hold	5,000	–	–	﹤0.01%	41
2023 Q2	$114K	Hold	5,000	–	–	﹤0.01%	53
2023 Q1	$150K	Hold	5,000	–	–	0.01%	47
2022 Q4	$149K	Hold	5,000	–	–	0.01%	56
2022 Q3	$155K	Hold	5,000	–	–	0.01%	63
2022 Q2	$227K	Hold	5,000	–	–	0.02%	42
2022 Q1	$231K	Hold	5,000	–	–	0.01%	51
2021 Q4	$580K	Hold	5,000	–	–	0.02%	49
2021 Q3	$1.05M	Hold	5,000	–	–	0.03%	48
2021 Q2	$976K	Hold	5,000	–	–	0.02%	52
2021 Q1	$1.45M	Buy	+5,000	New	+$1.67M	0.03%	63

Other funds holding FTH

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of America

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Millennium Management

Millennium Management New York $134B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return